Abstract
Objective: Carperitide, an α-human A-type natriuretic peptide, is commonly used for the treatment of acute decompensated heart failure (ADHF). The aim of this study was to investigate the effects of carperitide
administration on mortality and outcomes in patients with ADHF in a multicenter observational study in Japan using propensity score matching.
Methods: We performed a subanalysis of the HIJ-HF II (The Heart Institute of Japan Heart Failure II) study of hospitalized patients with ADHF in 10 Japanese hospitals. Patients receiving carperitide for the treatment of ADHF and those not receiving carperitide were selected from this database. The primary outcome was in-hospital death. The secondary outcomes were length of hospital stay, EuroQol five-dimensional (EQ-5D) index score and EQ visual analog scale (VAS) score at hospital discharge, one-year postdischarge mortality and rehospitalization due to worsening HF within 1 year of discharge.
Results: Of the 1,245 patients, 371 (29.8％) received intravenous carperitide. Propensity score matching resulted in 168 pairs. In-hospital death was not significantly different between the carperitide and noncarperitide groups (odds ratio［OR］1.07, 95％CI 0.51-2.25). The length of hospital stay, EQ-5D index score and EQ VAS score were not significantly different between the two groups. One-year mortality after hospital discharge or one-year rehospitalization due to worsening HF was not significantly different between both groups (OR 0.69, 95％CI 0.32-1.49; OR 1.06, 95％CI 0.56-2.03).
Conclusions: The findings of this propensity score-matched substudy suggested no significant difference in in-hospital mortality or long-term outcomes between carperitide and noncarperitide therapy in ADHF patients.
